ישראל - עברית - Ministry of Health

trupharm marketing 1985 ltd. - dithranol 0.1 %w/w - cream - dithranol - topical treatment of sub-acute & chronic psoriasis,including psoriasis of the scalp.

ישראל - עברית - Ministry of Health

trupharm marketing 1985 ltd. - dithranol 0.25 %w/w - cream - dithranol - topical treatment of sub-acute & chronic psoriasis,including psoriasis of the scalp.

ישראל - עברית - Ministry of Health

trupharm marketing 1985 ltd. - dithranol 1 %w/w - cream - dithranol - topical treatment of sub-acute & chronic psoriasis,including psoriasis of the sculp.

ישראל - עברית - Ministry of Health

trupharm marketing 1985 ltd. - dithranol 0.5 %w/w - cream - dithranol - topical treatment of sub-acute & chronic psoriasis,including psoriasis of the scalp.

ישראל - עברית - Ministry of Health

trupharm marketing 1985 ltd. - dithranol 2 %w/w - cream - dithranol - topical treatment of subacute and chronic psoriasis including psoriasis of the scalp.

ישראל - עברית - Ministry of Health

gamida care ltd., israel - ethanol; propanol - תמיסה - propanol 18 %w/v; ethanol 45 %w/v - propanol, combinations

ישראל - עברית - Ministry of Health

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 400 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.

ישראל - עברית - Ministry of Health

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 600 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.

ישראל - עברית - Ministry of Health

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 75 mg - darunavir - darunavir - adult patients : prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment -experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment -experienced adult patients .pediatric patients :prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv in pediatric patients 6 years of age and older. this indication is based on week 24 analyses of plasma hiv rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment -experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric the following points should be considered when ini

ישראל - עברית - Ministry of Health

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 150 mg - darunavir - darunavir - adult patients : prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment -experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment -experienced adult patients .pediatric patients :prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv in pediatric patients 6 years of age and older. this indication is based on week 24 analyses of plasma hiv rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment -experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric the following points should be considered when ini